Dr. Lallas on Challenges With Immunotherapy in Genitourinary Malignancies

Costas Lallas, MD
Published: Wednesday, May 24, 2017



Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses challenges with immunotherapy in genitourinary (GU) malignancies.

Most checkpoint inhibitors in GU cancers are still relatively new, says Lallas. Physicians want to be sure that they are giving the patients what they believe to be the best treatment, but as of now there is not a lot of information regarding immunotherapy in these diseases.

Additionally, the cost of these agents is very high, says Lallas, but as more positive data and knowledge about immunotherapy comes out in this disease, the cost may become more reasonable.
 


Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses challenges with immunotherapy in genitourinary (GU) malignancies.

Most checkpoint inhibitors in GU cancers are still relatively new, says Lallas. Physicians want to be sure that they are giving the patients what they believe to be the best treatment, but as of now there is not a lot of information regarding immunotherapy in these diseases.

Additionally, the cost of these agents is very high, says Lallas, but as more positive data and knowledge about immunotherapy comes out in this disease, the cost may become more reasonable.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x